Anecortave Acetate Risk Reduction Trial (AART)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
The purpose of this study is to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of dry age-related macular degeneration (AMD) in patients who are at-risk for progressing to wet AMD.
Epistemonikos ID: 3e4fb64069977903d2e83b0b97ef8e1c3477c223
First added on: May 04, 2024